中华皮肤科杂志 ›› 2014, Vol. 47 ›› Issue (4): 284-286.

• 研究报道 • 上一篇    下一篇

白介素25、33在慢性荨麻疹患者外周血中的表达及意义

李玲玲1,张玉杰2,尹利莎2,董大群3,安荣真4,张俊花4   

  1. 1. 淄博市第三人民医院皮肤科
    2. 滨州医学院附属医院
    3. 山东省滨州医学院附属医院
    4. 山东省滨州医学院附院皮肤科
  • 收稿日期:2013-03-25 修回日期:2013-12-30 出版日期:2014-04-15 发布日期:2014-04-01
  • 通讯作者: 张玉杰 E-mail:byfyzyj@126.com

Expressions of interleukin-25 and interleukin-33 in peripheral blood of patients with chronic urticaria and their significance

  • Received:2013-03-25 Revised:2013-12-30 Online:2014-04-15 Published:2014-04-01

PDF

6

赞

摘要： 【摘要】 目的 探讨慢性荨麻疹患者外周血中白介素（IL）-25、IL-33的表达及意义。 方法 慢性荨麻疹患者93例，健康人对照30例。慢性荨麻疹组口服氯雷他定治疗4周。采用酶联免疫吸附试验（ELISA）检测外周血IL-25、IL-33水平，分析慢性荨麻疹患者治疗前IL-25、IL-33水平与病情严重程度的相关性。 结果 慢性荨麻疹患者治疗前IL-25、IL-33水平分别为（139.86 ± 28.48）、（91.95 ± 21.88） ng/L，健康对照组分别为（114.41 ± 34.00）、（79.80 ± 30.72） ng/L，慢性荨麻疹患者IL-25、IL-33水平较健康对照组显著升高（P ＜ 0.01和 ＜ 0.05），且与患者病情呈正相关（r分别为0.38和0.42，均P ＜ 0.01）。慢性荨麻疹患者口服氯雷他定治疗4周后，有效率为81.72%，患者IL-25表达水平为（116.48 ± 21.94） ng/L，较治疗前明显降低（P ＜ 0.01），与健康对照组相比差异无统计学意义（P ＞ 0.05）；IL-33表达水平为（90.88 ± 20.62） ng/L，较治疗前差异无统计学意义（P ＞ 0.05）。 结论 IL-25、IL-33在慢性荨麻疹患者外周血中表达水平升高，并与病情严重程度呈正相关。

关键词: 荨麻疹, 白细胞介素33, 白细胞介素25, 氯雷他定

Abstract: Li Lingling, Zhang Yujie*, Yin Lisha, Dong Daqun, An Rongzhen, Zhang Junhua. *Department of Dermatology, Affiliated Hospital of Binzhou Medical College, Binzhou 256603, Shandong, China Corresponding author: Zhang Yujie, Email: byfyzyj@126.com 【Abstract】 Objective To detect the expression levels of interleukin （IL）-25 and IL-33 in peripheral blood of patients with chronic urticaria. Methods Ninety-three patients with chronic urticaria were included in this study along with 30 healthy individuals． All the patients were treated with loratadine for four weeks. Blood samples were collected from the healthy controls and patients before and after the four-week treatment. Enzyme-linked immunosorbent assay （ELISA） was performed to detect the serum levels of IL-25 and IL-33. The relationship between the expression levels of the two cytokines and urticaria severity was analyzed. Results The serum levels of IL-25 and IL-33 in the patients before treatment were significantly higher than those in the healthy controls （IL-25, 139.86 ± 28.48 vs. 114.41 ± 34.00 ng/L, P < 0.01; IL-33, 91.95 ± 21.88 vs. 79.80 ± 30.72 ng/L, P < 0.05）, and positively correlated with the severity of urticaria （r = 0.38, 0.42, respectively, both P < 0.01）. After four weeks of treatment, clinical improvement was observed in 81.72% of these patients with a significant decrease in the serum IL-25 level （116.48 ± 21.94 vs. 139.86 ± 28.48 ng/L, P < 0.01）, but no obvious changes in the serum IL-33 level （90.88 ± 20.62 vs. 91.95 ± 21.88 ng/L, P ＞ 0.05） compared with those before treatment. Conclusions The expressions of IL-25 and IL-33 are elevated in peripheral blood of patients with chronic urticaria, and positively correlated with the severity of urticaria.

Key words: Urticaria, Interleukin-33, Interleukin-25, Loratadine